Navigation Links
Weikang Bio-Technology Issues 2010 and 2011 Fiscal Year Guidance
Date:9/14/2010

Weikang Bio-Technology Issues 2010 and 2011 Fiscal Year Guidance -- HARBIN, China, Sept. 14 /PRNewswire-Asia-FirstCall/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
OTC, SmallCap, Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Earnings Forecasts & Projections Click to view news release full screen  

Weikang Bio-Technology Issues 2010 and 2011 Fiscal Year Guidance

 

HARBIN, China, Sept. 14 /PRNewswire-Asia-FirstCall/ -- Weikang Bio-Technology Group Co., Inc. (OTC Bulletin Board: WKBT) ("Weikang" or the "Company"), a leading developer, manufacturer and marketer of Traditional Chinese Medicine (TCM), Western prescription and OTC pharmaceuticals and other health and nutritional products in the People's Republic of China, today announced 2010 and 2011 fiscal year guidance.

For the fiscal year 2010, Weikang Bio-Technology expects revenue of $55 million, gross profit of $33 million and net profit of $21 million. The Company is also targeting fiscal year 2011 revenue growth to be in the range of 30% to 50% over 2010 revenue. Average gross margin for 2011 is expected to be approximately 60% as the Company's sales of higher margin products increases as a percentage of overall revenue. Revenue growth is supported by the Company's solid pipeline of new therapeutics to be launched in fourth quarter 2010 and the first half of 2011. In addition to a variety of sales and media promotions, Weikang Bio-Technology will be introducing their new therapeutics to a large number of new retailers and distributors at the 64th National Drug Exchange Convention in December.

"We are upbeat about our future growth opportunities as we continue to strengthen our market position by broadening our sales territory and launching new and exciting therapeutics that have a wide market potential. In the fourth quarter of 2010 and the first half of 2011, we intend to launch five new proprietary therapeutics; Sha Bai Shuanghuai, Gouqi Xi Pu, Shouwu Long Life and Lysozyme Buccal and Ha Ge Jiao Lan," commented Dr. Ying Wang, Chairman & CEO of Weikang Bio-Technology Group Co., Inc. "Our new product launches are supported through a variety of marketing efforts including providing sales incentives to our distributors as well as regular media promotions."

The new therapeutics have been approved by the State Food and Drug Administration (SFDA). A brief description of the new therapeutics expected to be launched are listed below:

Rongrun Brand -- Sha Bai Shuanghuai is primarily used for preventing and treating cardio and cerebrovascular diseases such as coronary heart disease, angina, hyperlipemia, hypertension and cerebral arteriosclerosis. -- Gouqi Xi Pu is primarily used to remove free radicals, provides anti-aging protection and enhances the immune system. -- Ha Ge Jiao Lan is primarily used for treating symptoms associated with menopause as well as increases youthful vitality and balances hormones. TianFang Brand -- Shouwu Long Life is primarily used to improve the function of the kidney and liver as well as enhance overall energy levels. -- Lysozyme Buccal is primarily used to prevent and treat respiratory tract infection including inflammation of the pharynx and larynx. About Weikang Bio-Technology Group Co., Inc.

Weikang Bio-Technology Group Co., Inc. is principally engaged in developing, manufacturing and distributing Traditional Chinese Medicine (TCM), and health and nutritional supplements in China, in compliance with requisite Chinese licenses and approvals. The Company is also expanding its business scope to develop, manufacture and distribute Chinese herbal extract products and GMP certified western prescription and OTC pharmaceuticals through its acquisition of Tianfang. For more information, please visit http://www.weikangbio.com .

Safe Harbor Statement

This press release contains certain statements that may include "forward-looking statements." All statements other than statements of historical fact included herein are "forward-looking statements." These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

For more information, please contact: Company contact: Ren Hu, VP of Finance Weikang Bio-Technology Group Co., Inc. US Tel: +1-201-887-0415 China cell: +86-137-1872-8163 Email: rhu@weikangbio.com Investors Relation contacts: John Marco, Partner, Elite IR Tel: +1-310-819-2948 Email: John.marco@elite-ir.com Leslie J. Richardson, Partner, Elite IR Tel: +852-3183-0283 Email: Leslie.richardson@elite-ir.com
'/>"/>

SOURCE Weikang Bio-Technology Group Co., Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Weikang Bio-Technology to Present at Rodman and Renshaws Annual Global Investment Conference on September 14th 2010
2. Weikang Bio-Technology Reports Second Quarter 2010 Financial Results
3. Cold Chain MENA 2010 to Focus on Critical Industry Issues
4. United Nations' World Population Day Calls Attention to Key Global Issues
5. Florida Water Resources Annual Conference Focuses on Numeric Nutrient and Other Water Issues
6. Adventus Group Issues Guidelines Surrounding Use of Zero Valent Iron with Emulsified Vegetable Oil
7. Layered graphene sheets could solve hydrogen storage issues
8. No New Findings in Atrazine Study Promoted by Discredited Researcher, According to the Hudson Institute Center for Global Food Issues
9. PAREXEL Issues Updated Financial And Operational Information
10. Squeezing Costs out of Healthcare Tops PricewaterhouseCoopers' List of Health Industry Issues in 2010
11. Surety Leads Web Symposium to Address Data Integrity Issues in Bio-Sciences Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... ... innovative medical technologies, services and solutions to the healthcare market. The company's primary ... various distribution, manufacturing, sales and marketing strategies that are necessary to help companies ...
(Date:6/24/2016)... 24, 2016  Regular discussions on a range of subjects ... the two entities said Poloz. Speaking at a ... , he pointed to the country,s inflation target, which ... "In certain areas ... have common economic goals, why not sit down and address ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced ... this eBook by providing practical tips, tools, and strategies for clinical researchers. , ...
(Date:6/23/2016)... June 23, 2016 A person commits a crime, ... scene to track the criminal down. An outbreak ... and Drug Administration (FDA) uses DNA evidence to track down ... Sound far-fetched? It,s not. The FDA has increasingly used ... investigations of foodborne illnesses. Put as simply as possible, whole ...
Breaking Biology Technology:
(Date:4/19/2016)... , UAE, April 20, 2016 ... implemented as a compact web-based "all-in-one" system solution for ... biometric fingerprint reader or the door interface with integration ... modern access control systems. The minimal dimensions of the ... readers into the building installations offer considerable freedom of ...
(Date:4/13/2016)... physicians supporting Medicaid patients in Central Florida ... telehealth thanks to a new partnership with higi.   ... can routinely track key health measurements, such as blood ... they opt in, share them with IMPOWER clinicians through ... location at no cost. By leveraging this data, IMPOWER ...
(Date:3/23/2016)... 23, 2016 ... Gesichts- und Stimmerkennung mit Passwörtern     ... MESG ), ein führender Anbieter digitaler ... mit SpeechPro zusammenarbeitet, um erstmals dessen Biometrietechnologie ... die Möglichkeit angeboten, im Rahmen mobiler Apps ...
Breaking Biology News(10 mins):